Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Syros Pharmaceuticals, Inc. (SYRS : NSDQ)
 
 • Company Description   
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Number of Employees: 124

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.73 Daily Weekly Monthly
20 Day Moving Average: 1,016,096 shares
Shares Outstanding: 62.82 (millions)
Market Capitalization: $45.59 (millions)
Beta: 2.14
52 Week High: $7.03
52 Week Low: $0.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -40.03% -34.33%
12 Week -43.31% -36.28%
Year To Date -77.74% -72.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
35 Cambridge Park Drive 4th Floor
-
CAMBRIDGE,MA 02140
USA
ph: 617-744-1340
fax: -
hannahd@sternir.com http://www.syros.com
 
 • General Corporate Information   
Officers
Nancy Simonian - President; Chief Executive Officer and Director
Peter Wirth - Chairman of the Board of Directors
Jason Haas - Chief Financial Officer
Srinivas Akkaraju - Director
Mark J. Alles - Director

Peer Information
Syros Pharmaceuticals, Inc. (CORR.)
Syros Pharmaceuticals, Inc. (RSPI)
Syros Pharmaceuticals, Inc. (CGXP)
Syros Pharmaceuticals, Inc. (BGEN)
Syros Pharmaceuticals, Inc. (GTBP)
Syros Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87184Q107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 62.82
Most Recent Split Date: (:1)
Beta: 2.14
Market Capitalization: $45.59 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.72
Price/Cash Flow: -
Price / Sales: 1.89
EPS Growth
vs. Year Ago Period: -73.91%
vs. Previous Quarter: 4.76%
Sales Growth
vs. Year Ago Period: 13.26%
vs. Previous Quarter: -29.93%
ROE
03/31/22 - -104.21
12/31/21 - -75.67
09/30/21 - -77.65
ROA
03/31/22 - -51.51
12/31/21 - -40.27
09/30/21 - -40.41
Current Ratio
03/31/22 - 4.22
12/31/21 - 4.33
09/30/21 - 5.13
Quick Ratio
03/31/22 - 4.22
12/31/21 - 4.33
09/30/21 - 5.13
Operating Margin
03/31/22 - -414.63
12/31/21 - -379.44
09/30/21 - -432.57
Net Margin
03/31/22 - -403.99
12/31/21 - -368.52
09/30/21 - -434.32
Pre-Tax Margin
03/31/22 - -403.99
12/31/21 - -368.52
09/30/21 - -434.32
Book Value
03/31/22 - 1.01
12/31/21 - 1.38
09/30/21 - 1.71
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.62
12/31/21 - 0.47
09/30/21 - 0.38
Debt-to-Capital
03/31/22 - 38.20
12/31/21 - 32.12
09/30/21 - 27.49
 

Powered by Zacks Investment Research ©